FY2026 EPS Estimates for Liquidia Reduced by HC Wainwright

Key Points

• HC Wainwright cut Liquidia’s FY2026 EPS estimate to $3.44 from $3.97, though it remains above the $2.57 consensus forecast. The firm also projects EPS of $6.41 in FY2027 and $10.08 by FY2030.
• Liquidia’s second-quarter revenue surged 1,842% year over year to $171.68 million, topping estimates of $168.48 million, driven by YUTREPIA sales. However, EPS of $0.74 narrowly missed the $0.76 consensus.
• Analyst sentiment is mixed, with a consensus “Hold” rating and average price target of $98.08. Meanwhile, insiders sold roughly $123 million in shares over the past 90 days.

Liquidia Corporation (NASDAQ:LQDA - Free Report) - Research analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Liquidia in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Fein now expects that the company will earn $3.44 per share for the year, down from their previous forecast of $3.97. The consensus estimate for Liquidia's current full-year earnings is $2.57 per share. HC Wainwright also issued estimates for Liquidia's Q4 2026 earnings at $1.18 EPS, FY2027 earnings at $6.41 EPS, FY2028 earnings at $7.39 EPS, FY2029 earnings at $9.01 EPS and FY2030 earnings at $10.08 EPS.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts' consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the prior year, the company earned ($0.49) EPS. The firm's revenue for the quarter was up 1842.1% on a year-over-year basis.

Other equities research analysts also recently issued research reports about the stock. Wells Fargo & Company increased their target price on shares of Liquidia from $62.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday. Jefferies Financial Group restated a "buy" rating and issued a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Liquidia in a research report on Friday, July 17th. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Finally, Piper Sandler set a $129.00 target price on Liquidia in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $98.08.

Liquidia Stock Performance

NASDAQ LQDA opened at $74.44 on Monday. The firm's fifty day moving average is $78.67 and its two-hundred day moving average is $55.22. Liquidia has a one year low of $21.15 and a one year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm has a market cap of $6.66 billion, a PE ratio of 54.34 and a beta of 0.58.

Insiders Place Their Bets

In other news, Director Paul B. Manning sold 200,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the transaction, the director owned 716,311 shares in the company, valued at $45,779,436.01. This trade represents a 21.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Stephen M. Bloch sold 242,269 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the transaction, the director owned 1,176,184 shares of the company's stock, valued at $82,838,639.12. This represents a 17.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 1,756,861 shares of company stock worth $122,981,112. Corporate insiders own 25.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia during the 4th quarter valued at approximately $25,000. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter worth approximately $25,000. Covestor Ltd grew its holdings in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after acquiring an additional 359 shares during the period. Tower Research Capital LLC TRC increased its stake in Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock valued at $83,000 after purchasing an additional 4,927 shares in the last quarter. Finally, Globeflex Capital L P purchased a new position in Liquidia in the 2nd quarter valued at approximately $175,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source